Format

Send to

Choose Destination
Exp Hematol. 2014 May;42(5):332-46. doi: 10.1016/j.exphem.2014.02.002. Epub 2014 Mar 22.

Biomanufacture of human platelets for transfusion: Rationale and approaches.

Author information

1
Materials Science and Engineering, Commonwealth Scientific Industrial Research Organisation, Victoria, Australia; Australian Regenerative Medicine Institute, Monash University, Victoria, Australia.
2
Materials Science and Engineering, Commonwealth Scientific Industrial Research Organisation, Victoria, Australia; Australian Regenerative Medicine Institute, Monash University, Victoria, Australia. Electronic address: david.haylock@csiro.au.

Abstract

Platelets for transfusion obtained from volunteer blood donors are a limited resource. Given the increased range of donor restrictions to prevent transmission of disease and the decline in volunteer blood donors, there is a diminishing supply of blood for transfusion. Production of mature blood cells from hematopoietic stem cells via large-scale manufacture is an alternative way of meeting transfusion demands. In this review, we provide a detailed outline of the challenges and opportunities for the biomanufacture of platelets. We describe the scale required for platelet biomanufacture to deliver sufficient cells for transfusion, provide a brief outline of the current understanding of megakaryopoiesis and thrombogenesis, and highlight how the current understanding impacts the design of culture systems and bioreactors for producing platelets.

PMID:
24667682
DOI:
10.1016/j.exphem.2014.02.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center